Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 3 ( March, 2022 ) > List of Articles


Rhinosinus Mucormycosis with Drug-induced Pancytopenia in an Immunocompromised Severe COVID-19 Patient: A Success

Anurag Mahajan, Vineeta Singh Tandon

Keywords : COVID pneumonia, Diabetes, Immunocompromised, Pancytopenia, Rhinosinus mucormycosis

Citation Information : Mahajan A, Tandon VS. Rhinosinus Mucormycosis with Drug-induced Pancytopenia in an Immunocompromised Severe COVID-19 Patient: A Success. Indian J Crit Care Med 2022; 26 (3):395-398.

DOI: 10.5005/jp-journals-10071-24134

License: CC BY-NC 4.0

Published Online: 30-03-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Secondary infections in coronavirus disease (COVID) are becoming common. We report a case of a female known case of diabetes, sarcoidosis on steroids and methotrexate admitted with COVID pneumonia. She was treated with steroids, remdesivir, and anticoagulants and was discharged. She revisited the hospital after 2 months with complaints of severe right-sided headache, eye pain, and vomiting. Magentic resonance image of brain and paranasal sinus revealed possibility of invasive rhinosinus mucormycosis. Functional endoscopic sinus surgery (FESS) was done and culture showed growth of mucor and methicillin resistant staphylococcus aureus (MRSA) following which she was started on amphotericin B and antibiotics. She also developed methotrexate and amphotericin B-induced pancytopenia for which injection folinic acid, granulocyte-colony stimulating factor (G-CSF), and erythropoietin were given and was switched over to liposomal amphotericin B. After 5 days of ventilatory support, she was discharged in a stable condition. Extensive steroids in an immunocompromised patient might have led to this event hence physicians should always keep this possibility of secondary fungal infection in COVID patients for understanding the impact of disease.

  1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis 2020;71(9):2459–2468. DOI: 10.1093/cid/ciaa530.
  2. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A Multicentre Observational Study on the Epidemiology, Risk Factors, Management and Outcomes of Mucormycosis in India. Clin Microbiol Infect 2020;26(7):944.e9–944.e15. DOI: 10.1016/j.cmi.2019.11.021. Epub 2019 Dec 4.
  3. Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O. Diabetes and Mucormycosis: A Complex Interplay. Diabetes Metab 2012;38(3): 193–204. DOI: 10.1016/j.diabet.2012.01.002. Epub 2012 Mar 3.
  4. McNulty JS. Rhinocerebral Mucormycosis: Predisposing Factors. Laryngoscope 1982;92(10 Pt 1):1140–1143. PMID: 7132514.
  5. Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options. Ann Pharmacother 2016;50(9):747–757. DOI: 10.1177/1060028016655425. Epub 2016 Jun 15.
  6. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival Factors in Rhino-Orbital-Cerebral Mucormycosis. Surv Ophthalmol 1994;39(1):3–22. DOI: 10.1016/s0039-6257(05)80041-4.
  7. Werthman-Ehrenreich A. Mucormycosis with Orbital Compartment Syndrome in a Patient with COVID-19 [published online ahead of print, 2020 Sep 16]. Am J Emerg Med 2020;S0735–6757(20)30826-3. DOI:10.1016/j.ajem.2020.09.032.
  8. Aribandi M, McCoy VA, Bazan C 3rd. Imaging Features of Invasive and Noninvasive Fungal Sinusitis: A Review. Radiographics 2007;27:1283. Available from:
  9. Guarner J, Brandt ME. Histopathologic Diagnosis of Fungal Infections in the 21st Century. Clin Microbiol Rev 2011;24(2):247–280. DOI: 10.1128/CMR.00053-10.
  10. Andes DR, Ghannoum MA, Mukherjee PK, et al. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrob Agents Chemother 2018;63(1):e01634–18. DOI: 10.1128/AAC.01634-18.
  11. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016;16(7):828–837. DOI: 10.1016/S1473-3099(16)00071-2.
  12. Weprin BE, Hall WA, Goodman J, Adams GL. Long-term Survival in Rhinocerebral Mucormycosis. Case Report. J Neurosurg 1998;88(3):570–575. DOI: 10.3171/jns.1998.88.3.0570.
  13. Shah PD, Peters KR, Reuman PD. Recovery from Rhinocerebral Mucormycosis with Carotid Artery Occlusion: A Pediatric Case and Review of the Literature. Pediatr Infect Dis J 1997;16(1):68–71. DOI: 10.1097/00006454-199701000-00015.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.